KC-3168

CHOK1-cyno-CD79a-T2A-CD79b-Cell-Line

×
Please enable JavaScript in your browser to complete this form.
34170
Home » CHOK1-cyno-CD79a-T2A-CD79b-Cell-Line

Background of CHOK1-cyno-CD79a-T2A-CD79b-Cell-Line

Both CD79A and CD79B are members of the immunoglobulin superfamily, and CD79A is encoded by the mb-1 gene on chromosome 19, while CD79B is encoded by the B29 gene on chromosome 17.Both chains of CD79 contain an immune receptor tyrosine activation motif (ITAM) at their cytoplasmic end that conducts a signal in B cells similar to the cellular signal generated by CD3 when the T cell receptor is activated.

Specifications

Catalog NumberKC-3168
Cell Line NameCHOK1-cyno-CD79a-T2A-CD79b-Cell-Line
Host Cell LineCHOK1
DescriptionStable CHOK1 cell line expressing exogenous cyno CD79a T2A CD79b gene
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640 + 20% FBS + 10% DMSO
Propagation MediumRPMI1640 + 10% FBS + 10μg/ml Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:5 every 2-3 days; seed out at about 1-3 × 105 cells/ml
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

CHOK1 cyno CD79a T2A CD79b Cell Line was generated using a lentiviral vector expressing the cyno CD79a T2A CD79b sequence.

Characterization

Figure 1: Characterization of cyno CD79a T2A CD79b overexpression in the CHOK1 cyno CD79a T2A CD79b stable clone using FACS.

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 supplemented with 10% FBS and 10μg/mL Puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage

References

  1. Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB,Irish JM, Wälchli S, Myklebust JH. Mechanism of CD79A and CD79B Support for IgM+B Cell Fitness through B Cell Receptor Surface Expression. J Immunol. 2022 Nov15;209(10):2042-2053. doi: 10.4049/jimmunol.2200144. PMID: 36426942; PMCID:PMC9643646.
    2. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis,
  2. risk stratification, and treatment. Am J Hematol. 2019 May;94(5):604-616. doi:10.1002/ajh.25460. PMID: 30859597.
    3. Li S, Borowitz MJ. CD79a(+) T-cell lymphoblastic lymphoma with coexistingLangerhans cell histiocytosis. Arch Pathol Lab Med. 2001 Jul;125(7):958-60.doi:10.5858/2001-125-0958-CTCLLW. PMID: 11419987.
    4. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA,
  3. Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu
  4. SF, Yue P, Zheng B, Ebens A, Polson AG. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500.Epub 2009 Jul 24. PMID: 19633198.
Please enable JavaScript in your browser to complete this form.